|
| 产地 | 中国 |
| 品牌 | Chemstan |
| 货号 | CSD00427 |
| 保存条件 | store at -80℃ |
| 用途 | 仅用于科研用途 |
| 应用范围 | |
| 抗原来源 | CHO cells |
| CAS编号 | 1638338-43-8 |
| 保质期 | 一年 |
| 抗体名 | Navicixizumab ( 那赛昔珠单抗 ) |
| 是否单克隆 | |
| 克隆性 | |
| 靶点 | DLL4/VEGFA[Homo sapiens] |
| 适应物种 | |
| 形态 | |
| 宿主 | |
| 标记物 | |
| 包装规格 | 100μg |
| 纯度 | % |
| 亚型 | |
| 标识物 | |
| 浓度 | 95% |
| 免疫原 | |
| 是否进口 | 否 |
Navicixizumab is under investigation in clinical trial NCT02298387 (A Phase 1 Study of Navicixizumab in Subjects With Solid Tumors).
货号（Catalog No.）
CSD00427
通用名INN
Navicixizumab
纯度(Purity)
>95%
浓度( Concentration)
1mg/ml
Formulation
PBS buffer pH7.5
Source
CHO cells
内毒素(Endotoxin level)
Please contact with the lab for this information.
产品描述(Description)
Navicixizumab is under investigation in clinical trial NCT02298387 (A Phase 1 Study of Navicixizumab in Subjects With Solid Tumors).
别名(Alternative names)
OMP-305B83
靶点;物种(Specificity target name;species)
DLL4/VEGFA[Homo sapiens]
种类(Species)
Chimeric,Humanized
受体鉴定(Receptor identification)
IgG2-kappa
